Neurosense Therapeutics Ltd. (NRSN) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
NeuroSense Therapeutics Ltd. has announced promising results from its phase 2b PARADIGM study of PrimeC for ALS treatment, showing a significant slowing of disease progression and up to 73% improvement in complication-free survival. The company is poised to discuss these findings with the FDA to chart a course for the drug’s future. These breakthroughs offer hope for better therapeutic options in the fight against ALS, a disease with a high unmet medical need and limited treatment options.
For further insights into NRSN stock, check out TipRanks’ Stock Analysis page.
